Lpeople with overweight y obese con heart disease They had less odds of to die If they took semaglutida, indicate the results of a three-year trial.
Los adults with cardiovascular disease y overweight They took semaglutida or a placebo and were monitored as part of a funded trial by the manufacturer of semaglutide Novo Nordisk.
After an average of three years, 833 of the 17,500 participants had died. People in the group taking semaglutide were 19 percent less likely to die, 15 percent less likely to die from heart problems and 23 percent less likely to die from non-heart-related causes, including Covid-19.
The pandemic began during the trial, and about 1 in 4 participants reported contracting the virus. Scientists at Harvard Medical School found that semaglutide didn’t seem to make any difference when it came to the speed at which participants developed Covid-19.
However, among those who did contract the virus, subjects taking semaglutide were less likely to develop serious health consequences, 232 compared with 277, or die, 43 compared with 65, from Covid-19.
Trial participants taking semaglutide received weekly injections of 2.4 milligrams of the drug, equivalent to taking Wegovy, the Novo Nordisk brand name for semaglutide, when prescribed for weight loss.
SEMAGLUTIDE PREVENTS RISK OF DEATH WITH COVID-19
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that attempts to mimic the fullness hormone GLP-1. It has been shown to help control blood sugar, decrease appetite, slow digestion and speed up metabolism, the effect being that people taking the drug tend to eat less and lose weight.
Overweight and obesity are associated with an increased risk of premature death. Excess weight exacerbates risk factors for heart disease and is a risk factor for dying from heart-related diseases.
Higher body mass is also associated with an increased risk of dying from Covid-19. However, the study authors wrote that it may not be true that semaglutide reduces the risk of premature death from all causes, heart disease and Covid-19 simply by helping people lose weight.
They wrote that the differences they saw in the semaglutide group, compared with the placebo group, were more than would be expected based solely on the changes that would occur from weight loss.
The study was based on data from a randomized controlled trial called Effects of semaglutide on cardiovascular outcomes in patients with overweight or obesity, part of Novo Nordisk’s SELECT trials. N
(Published in cooperation with Newsweek. Published in cooperation with Newsweek)
Newsweek en Español also recommends these notes:
Where in the brain does love live? Science explains it
Zoo successfully produces world’s first snakes by artificial insemination
More than 1,000 viruses unknown to science found in melted ice
Extinction alert: the number of threatened fish species on the planet has increased fivefold
Saunas for frogs: the invention to prevent their extinction
The position Semaglutide: The weight loss drug that reduces the risk of death appeared first in Newsweek in Spanish.
